[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abuse-liability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abuse-liability":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100626381","early-phase-1-repeated-cbd-administration-and-cannabis-outcomes-100626381",false,"NCT07434895","Repeated CBD Administration and Cannabis Outcomes","The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study","Inclusion Criteria:\n\n* English-speaking, literate adults,\n* Male or female,\n* Between the ages of 18-55,\n* Body Mass Index from 18.5-32.0 kg\u002Fm2,\n* Not currently seeking treatment for cannabis or drug use,\n* Able to provide written informed consent and perform all study procedures,\n* If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n* Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and\n* Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.\n\nExclusion Criteria:\n\n* Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n* Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n* Current or past history of major psychiatric disorder that would limit ability to participate in the study,\n* Use of cannabis exclusively for medical reasons (no recreational use reported),\n* Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),\n* Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,\n* Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n* Clinically significant abnormal laboratory findings,\n* History of seizure disorder,\n* Clinically significant history of head injuries requiring medical management or long lasting sequalae, and\n* Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).",true,"ALL","18 Years","55 Years",{"count":21,"type":22},23,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.",[28,29,30],"Cannabis","Abuse Liability","Experimental Pain in Healthy Human Participants",[32,33,34],"marijuana","cannabidiol (CBD)","marijuana users","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":22},"2026-06-29",{"date":43,"type":22},"2029-12-01",{"name":45,"class":46},"Hannah Harris","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100508906","early-phase-1-pkpd-of-oral-and-vaporized-delta-9-tetrahydrocannabinol-thc-in-older-adults-100508906","NCT05906511","PK\u002FPD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults","Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults","Inclusion Criteria:\n\n1. Healthy male and female participants aged 65 ≥ years old\n2. Prior exposure to THC or cannabis least once in the last 10 years; 1-10 times in the last 20 years; or more than 20 times in their lifetime\n3. Capable of providing informed consent in English.\n\nExclusion Criteria:\n\n1. Meeting DSM-5 criteria for psychiatric\u002Fsubstance use disorders (SUD) other than tobacco use disorder, within the last year\n2. Current use of cannabinoid products, as evidenced by a urine drug screen\n3. Having a history of treatment for cannabis use disorder\n4. History of intent or current intent of abstaining from cannabis use\n5. Clinically significant medical disorders (e.g. liver\u002Fkidney dysfunction, immunosuppressing conditions, history or presence of epilepsy, seizures, head trauma with loss of consciousness)\n6. Medical conditions that increase the risk of respiratory problems (e.g. COPD, asthma, recuring bronchitis, reactive airway disorder)\\* (does not apply to the Oral THC Sub-Study)\n7. History of environmental sensitivities (e.g. bronchospastic allergies, multiple chemical sensitivities) or other airway sensitivities that require the use of an epi pen\\*(does not apply to the Oral THC Sub-Study)\n8. Neurological conditions that may change the response to nociceptive stimuli (e.g., stroke, neuropathy), or that lead to loss of balance, evidenced by a neuro-sensory exam\n9. Contraindications for exposure to nociceptive stimuli, such as untreated hypertension\n10. Current regular use of drugs known to affect pain, or that are prominent inducers or inhibitors of CYP2C9, CYP3A4, or UGTA19 (e.g., carbamazepine, valproate, fluvoxamine, and paroxetine)\n11. Major neurocognitive disorders precluding participation, evidenced by a clinical exam\n12. Abnormal EKG, arrythmia, vasospastic disease, chronic heart failure, or presence of a pacemaker\n13. Elevation of liver enzymes (ALT, AST) 2x the normal limit or higher\n14. Personal or family history of primary psychotic disorders, or mood disorders with psychotic features\n15. Current suicidal ideation\n16. Allergy or serious adverse reactions to sesame oil, THC, or cannabis\n17. Having received any drug as part of a research study within 30 days prior to receiving the study medication in the current study.","65 Years",{"count":57,"type":22},20,[25],"The overarching goal of this double-blind, placebo-controlled, crossover study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) effects of the main analgesic and psychoactive constituent of cannabis, delta-9 tetrahydrocannabinol (THC), among older adults - the fastest growing population of cannabis consumers, and the most likely age cohort to use cannabinoids to relieve pain. This protocol includes two sub-studies, each randomizing 20 men and women aged 65 years or older to receive two administration routes of THC; oral administration and vaporized administration.",[61,62,29],"Pain, Tolerance","Oral vs Vaporized THC",[64,65],"Pharmacokinetics THC","Pharmacodynamics THC","2026-02-19",{"date":68,"type":39},"2026-02-23",{"date":70,"type":39},"2023-10-17",{"date":72,"type":22},"2026-08-31",{"name":74,"class":46},"Yale University"]